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Background: Plateletpheresis using a leukocyte reduction system (LRS) traps
donor WBCs in the LRS chamber, which may lead to lymphopenia, especially
in frequent plateletpheresis donors. It seems plausible that this might cause
adverse effects. However, current knowledge about potential confounders and
donor health impacts is incomplete.
Donors and methods: Recent platelet donors and donations collected at Uni-
versity Hospital Regensburg from 2016 to 2019 using the Terumo BCT Trima
Accel LRS system were retrospectively analyzed and compared with historical
platelet donors and donations collected mainly with Fresenius Kabi Amicus
non-LRS system from 2010 to 2013. Additionally, recent donors were prospec-
tively surveyed using a health-related topics questionnaire.
Results: Analysis of 819 recent donors with 11,254 blood counts and 1464 ques-
tionnaires and 1011 historical donors with 12,848 blood counts revealed that
increased annual platelet donation frequencies were associated with decreased
lymphocyte counts in both groups. Median lymphocyte counts in recent donors
with no versus ≥24 previous annual donations declined from 2.0 to 1.2  103/μL
(p < 2.2  1016), and those in historical donors with no versus ≥24 previous
annual donations decreased from 2.0 to 1.5  103/μL (p = 6  104), respectively.
The questionnaire results showed that donation frequency and lymphopenia were
not associated with upper respiratory tract infection (URTI) incidence or duration,
but platelet donors who concomitantly donated granulocytes had significantly
shorter URTI durations than those who did not (p = .008).
Conclusion: This study confirmed that plateletpheresis-associated
lymphopenia occurs in LRS and to a lesser degree in non-LRS platelet donors,
but revealed no evidence of a negative impact on donor health.
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1 | INTRODUCTION
Platelet concentrates are obtained by two methods: by
pooling remainders from several whole blood donations
or by collecting platelets from a single donor by aphere-
sis. The advantage of the latter method is that it selec-
tively removes platelets and returns the remaining blood
components to the donor. Consequently, repeated plate-
let donations can be collected at short intervals.1 In the
European Union, platelet concentrates are leukoreduced
to <1  106 white blood cells (WBCs) per unit.2 The fil-
tered WBCs are either returned to the donor or trapped,
when using Terumo's Trima, within a so-called
leukoreduction system (LRS) chamber. After platelet
harvesting, the trapped WBCs are flushed out of the LRS
chamber (generally incompletely) and discarded or
donated to research. About 1  109 WBCs can be
obtained from one LRS.3, 4 This has led to the theory that
leukocyte trapping may result in leukopenia in plat-
eletpheresis donors.
There are numerous indications that leukopenia and
lymphopenia are independent risk factors for donor
health impairment. Recently, large cohort studies have
shown that lymphopenia (≤1.5  103 lymphocytes/μL)
in outpatients is associated with an increased risk of
cardiovascular and non-cardiovascular mortality, inde-
pendent of age.5 Moreover, lymphocyte counts were
found to decrease with aging.6 Another study revealed
that lymphopenia of <1.1  103/μL in the general popu-
lation is associated with an increased risk of a range
of different infectious diseases and infection-related
death, independent of age.7 Likewise, a recent analysis
of 1,390,801 plasma donations and 111,458 LRS and
non-LRS plateletpheresis donations revealed that
lymphopenia in frequent plateletpheresis donors with
high total donation counts was associated with an
increased risk of immunosuppression-related infections
and common bacterial infections.8
Lymphopenia from platelet donation was found to
occur with some of the earlier donation techniques used
in the 1980s. In one study, a 20% decrease in lymphocyte
counts was observed after 10 weekly platelet donations
prepared using the Haemonetics Model 30, which removes
as much as 30% of the donor's circulating lymphocytes per
donation.9 The introduction of leukodepleted blood prod-
ucts and newer apheresis technologies has reduced but not
eliminated this problem. Lymphocyte count decreases of
60/μL after four platelet donations on with Trima Accel
have been observed,10 one of the most widely used aphere-
sis systems today. Plateletpheresis-associated lymphopenia
was recently attributed to low CD4+ T-cell counts in fre-
quent donors with a high annual donation frequency on
the Trima Accel.11
Protecting healthy donors from harm arising from the
donation procedure is one of the foremost duties of blood
donation services. Therefore, it is important to know if
there is a relationship between plateletpheresis-
associated lymphopenia and the annual donation fre-
quency, total donation count, concomitant donation of
other blood components, and/or the type of plat-
eletpheresis system (e.g., with or without an LRS cham-
ber), and whether plateletpheresis-associated
lymphopenia is clinically relevant. Therefore, we per-
formed a retrospective multifactorial analysis of clinical,
demographic, and hematological data on recent (with
LRS) versus historical (mostly non-LRS) plateletpheresis
donors and donations and a prospective survey of leuko-
penia and health-related aspects in recent donors.
2 | DONORS AND METHODS
All eligible plateletpheresis donors processed by the local
blood donation service of the University Hospital Regens-
burg, Germany from 01/01/2010 to 12/31/2013, whose
donations were collected mainly without an LRS cham-
ber (historical donors) and those processed from
01/01/2016 to 12/31/2019, whose donations were col-
lected with an LRS chamber (recent donors), were
assessed for eligibility in the retrospective analysis of
donor and donation-specific data, including hematologi-
cal variables and donation type (platelets alone or with
granulocytes and/or mononuclear cells). However, blood
counts from donors mobilized for granulocyte donation
were excluded. The time range for the total platelet dona-
tion count was from 2005 to 2019.
Additionally, all recent platelet donors presenting at
our blood donation service from March 19 to November
29, 2019 were asked to complete a prospective question-
naire on health-related topics during each visit. The ques-
tionnaire included questions regarding their health
habits (e.g., physical activity and exercise), exposure to
environments associated with an increased risk of upper
respiratory tract infection (e.g., kindergartens, crowded
public areas, and public transport), sleep habits, and
infectious disease history as well as a personal “Cold
diary” and is provided translated in the Data S1. The
questionnaire was focused on respiratory tract infections,
as these were common in the pre-Corona era.
A total of 1531 questionnaires were submitted, 48 of
which had to be excluded (10 due to missing consent,
18 due to missing donation identification, and 20 due to
questionnaire submission without qualification for dona-
tion). After the remaining 1483 eligible questionnaires
were read into an electronic data processing system
(EvaSys v8.0, Lüneburg, Germany), another 74 were
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excluded–two from mononuclear cell (MNC) donors and
72 from donors who presented without donation. Thus,
1409 out of 1642 platelet donations collected during the
questionnaire survey period were included from
320 donors in the analysis, corresponding to a participa-
tion rate of 86%.
The study was approved by the independent ethics
committee of the University of Regensburg (approval #
19-1348-101).
2.1 | Apheresis procedures
Plateletpheresis was performed using the non-LRS Ami-
cus Cell Separation Platform (Fresenius Kabi) in 73% of
donations obtained in 2010–2013 (with the remainder on
LRS-based donations), and with the LRS-based Trima
Accel Automated Blood Collection System (Terumo BCT)
in 99% of donations from 2016 to 2019. Generally, double
and single plateletpheresis products were collected from
all donors with platelet counts above 200/nL and 150/nL,
respectively, according to local and EU legislative regula-
tions.2 A maximum of 26 annual plateletpheresis was
allowed. The Trima Accel software offers no option to
flush the leukoreduction chamber apart from the
rinseback of the tubing system after platelet harvesting.
Mononuclear cell collection was performed using the
Cobe Spectra Auto-PBSC protocol (Terumo BCT) until
2014, and the Spectra Optia Continuous Mononuclear Cell
Collection (cMNC) program (Terumo BCT) thereafter, as
described previously for extracorporeal photopheresis.12
Granulocytapheresis was done as previously
described with the Cobe Spectra MNC program using
hydroxyethyl starch as the red blood cell (RBC) sedimen-
tation enhancer until 2014, and with the Optia cMNC
program using modified fluid gelatin to enhance RBC
sedimentation from then on.13
2.2 | Hematological analysis
Hematological parameters, including hemoglobin (Hb),
WBC, lymphocyte, monocyte, neutrophil, and platelet
counts, were routinely measured before each plat-
eletpheresis donation. This was done using the Sysmex
XE-5000 Automated Hematology Analyzer until 2016
and the Sysmex XN550 in the years thereafter.
2.3 | Statistical analysis
Donation history and hematological data were extracted
from the laboratory information system (Swisslab, Berlin,
Germany) and from the hospital's electronic data system
(SAP) and merged electronically with the questionnaire
data using R. Statistical analysis and graphical presenta-
tion of the data were performed in the R software envi-
ronment using the packages tidyr and dplyr, openxlsx,
reshape2, psych, nortest, data. table, gplots, rpart, rpart.
plot, randomForestSRC, ggRandomForests, ggrepel, and
ggplot2's cowplot as well as RColorBrewer and scales
along with their dependencies and is publicly available.14
Normal distribution was not found in any of the tested
data, as determined by Levene's test for equality of vari-
ances. Therefore, significance testing was performed with
Spearman's rank correlation coefficient, Wilcoxon,
and/or Kruskal-Wallis test, as appropriate. Factor analy-
sis was subsequently performed using the Kaiser–Meyer–
Olkin (KMO) test.
3 | RESULTS
3.1 | Recent donors (LRS donations)
The group of recent donors, who mainly underwent plat-
eletpheresis with an LRS chamber, comprised 819 donors
(467 male, 352 female) with 11,254 blood counts, 98.7%
of which were differential counts (Table 1). Some of these
had additional granulocyte (65) or mononuclear cell
donations (42), or both (40) at least once. The median
number of platelet donations was higher in men than in
women, both annually (♂ = 6.2, ♀ = 5.1) and overall
(♂ = 9, ♀ = 7). Likewise, the annual platelet donation
frequency in older donors aged 30 and older (five per
year) was higher than that in younger donors below the
age of 30 (two per year; p = 1.7  1014).
The association between donation frequency and
lymphopenia was highly significant, as expressed by a
rho of 0.41 (p < 2.2  1016, Figure 1a). Donors with
at least 24 plateletpheresis donations per 365-day
period had a median lymphocyte count of 1.24  103/μL
compared with 2.02  103/μL in donors without prior
plateletpheresis. Neutrophil and monocyte counts
showed minor dependency on the donation frequency:
rho values were 0.05 (p = 4.325  108) and 0.09
(p < 2.2  1016), respectively (Figure 1a).
Lymphopenia was also associated with the total plate-
let donation count, as expressed by a rho of 0.45
(p < 2.2  1016, Figure 1b). Associations for neutrophils
and monocytes were less pronounced, as reflected by a
rho 0.05 (p = 4.3  108) and 0.09 (p < 2.2  1016),
respectively (Figure 1b).
The annual platelet donation frequency and total
platelet donation count (cumulative) were highly associ-
ated with each other, and both were associated with
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TABLE 1 Donor characteristics
Male Female
Historical group of mostly non-LRS plateletpheresis donors (01/01/2010–12/31/2013)
Number of donors (n = 1011) 565 446
Hematological test visits (n = 12,848) 7987 4861





Median age 26.0 (18.6–58.9) 26.0 (18.3–57.8)
Age at donation 27.6 (18.3–60.7) 28.9 (18.2–59.0)
Platelet donations (n)
Total 10 (0–148) 7 (0–103)
Annual 6.7 (0–33.2) 5.1 (0–28.1)
Concomitant MNC donations (n)
Total 0 (0–6) 0 (0–0)
Annual 0 (0–1.8) 0 (0–2.0)
Concomitant granulocyte donations (n)
Total 0 (0–10) 0 (0–0)
Annual 0 (0–7.9) 0 (0–3.0)
Hematological parameters
Hb [g/dL] 15.1 (12.8–18.05) 13.2 (11–15.9)
WBC [103/μL] 5.80 (3.42–12.78) 6.32 (3.26–11.06)
Lymphocytes [103/μL] 1.88 (0.72–3.90) 2.04 (0.79–4.12)
Monocytes [103/μL] 0.54 (0.24–1.32) 0.48 (0.25–1.25)
Neutrophils [103/μL] 3.21 (1.39–7.65) 3.45 (1.25–8.95)
Platelets [103/μL] 234 (144–346) 262 (177–411)
Recent group of mostly LRS plateletpheresis donors (01/01/2016–12/31/2019)
Number of donors (n = 819) 467 352
Hematological test visits (n = 11,254) 7391 3863





Median age 26.3 (18.1–64.8) 25.5 (18.2–57.2)
Age at donation 28.7 (18.1–66.8) 26.7 (18.1–57.2)
Platelet donations (n)
Total 9 (0–218) 7 (1–159)
Annual 6.2 (0–28.1) 5.1 (0.1–26.1)
Concomitant MNC donations (n)
Total 0 (0–8) 0 (0–0)
Annual 0 (0–2.9) 0 (0–0)
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lymphopenia (Table 2 and Figure 2). Our data also confirm
the previously described age-dependent reduction of lym-
phocyte counts (p < 2.2  1016, Figure 3a). Further associ-
ations were found for concomitant MNC donations, but not
for concomitant granulocyte donations (Figure 3b,c).
3.2 | Historical donors (mostly non-LRS
donations)
Based on the hypothesis that plateletpheresis-associated
lymphopenia is caused by LRS chambers acting as WBC traps,
we retrospectively compared hematological parameters and
donation frequencies of recent plateletpheresis donors, whose
donations were collected using an LRS chamber, with those
of the historical donors, whose donations were predominantly
collected using the Amicus system, which operates without
an LRS chamber. The historical group comprised 1011 donors
with 12,848 blood counts, 12.0% of which were differential
counts (Table 1). Some of these had additional granulocyte
(64) or mononuclear cell donations (58) or both (23) at least
once. Platelet donation frequency-dependent lymphopenia
also occurred in this historic group, albeit to a weaker extent
(Figure 4a). Donors with 24 or more platelet donations in
the last 365 days had a median lymphocyte count of
1.53  103/μL in peripheral blood, whereas those with zero
previous annual plateletpheresis donations had a median of
1.96  103 lymphocytes/μL (p = .0006, Figure 4a,b).
3.3 | Multifactorial analysis of recent
donors with LRS donations
The different factors causing lymphopenia were dissected
in a multifactorial analysis (Figure 5). The Kaiser–
Meyer–Olkin (KMO) test of factorial adequacy revealed
that the measure of factoring adequacy was 0.67. KMO
values of 0.5 and higher generally indicate the appropriate-
ness of factor analysis. Two-factor maximum-likelihood
analysis, which clusters parameters independent of explan-
atory variables, revealed that Factor 2 (age, lymphocyte
count, annual platelet donation frequency, and total plate-
let donation count) explained 25% of the variance
(Figure 5a), while Factor 1 (annual and total number of
concomitant MNC and granulocyte donations) explained a
further 25% of the variance.
The most important variables for lymphopenia, iden-
tified using a tree-based approach computed with the
randomForestSRC package (Fast Unified Random For-
ests for Survival, Regression, and Classification), were
total platelet donation count followed by donor age,
length of the donor career, and annual platelet donation
frequency (Figure 5b).
Dependencies between median lymphocyte values and
explanatory variables were calculated with a recursive regres-
sion tree model (Figure 5c), which also identified the total
platelet donation count as the most important variable. More-
over, the decisive threshold number of plateletpheresis dona-
tions for lymphopenia was 29, and the effect was significant
(p = 0.005). In these two analyses, the age of the donor, the
length of the donor career, and the annual platelet donation
frequency were identified as other important variables,
whereas the number of concomitant MNC and granulocyte
donations played a subordinate role (Figure 5b,c).
3.4 | Lymphopenia and infections
LRS donors were surveyed about post-donation complica-
tions potentially caused by plateletpheresis, such as
TABLE 1 (Continued)
Male Female
Concomitant granulocyte donations (n)
Total 0 (0–17) 0 (0–0)
Annual 0 (0–3.4) 0 (0–0)
Hematological parameters
Hb [g/dL] 15.05 (13.3–17) 13.25 (12.1–15.7)
WBC [103/μL] 5.71 (3.54–10.86) 6.52 (4.02–12.02)
Lymphocytes [103/μL] 1.82 (0.78–3.35) 2.14 (0.89–4.66)
Monocytes [103/μL] 0.54 (0.27–1.28) 0.52 (0.26–0.1)
Neutrophils [103/μL] 3.12 (1.59–6.89) 3.58 (1.72–8.26)
Platelets [103/μL] 242 (166–416) 278 (181–420)
Note: Data are shown as median values with range in parentheses. Visits include all initial donor presentations, visits where donors were rejected, and
donation visits (including granulocyte donations) at which hematological testing was performed. The annual donation count is shown as a median value
calculated based on the donation frequency over the last 365 days.
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lymphopenia and upper respiratory tract infection
(URTI). Responses to infectious disease items were pro-
vided on 1464 of 1483 questionnaires. No infectious dis-
eases were reported in 1307 of 1464 cases (89.3%). Donor
lymphocyte counts correlated weakly with the reported
number of days with upper respiratory tract infection
(“URTI days”, Figure 6a), the number of URTI episodes
(“URTI count”, Figure 6c), and the duration of disease
between donations (“URTI duration”, Figure 6e), but
these trends were not statistically significant (p = 0.16,
0.16, and 0.22, and rho = 0.08, 0.08, and 0.09,
respectively).
The platelet donation frequency did not positively
correlate with the reported number of URTI days
(Figure 6b), URTI episodes (Figure 6d), or the duration of
disease between donations (URTI duration, Figure 6f).
The results for these aggregated data from 320 donors
were not significant (p = 0.26, 0.48, and 0.14, and
rho = 0.06, 0.04, and 0.12, respectively).
As donors with high donation frequencies were
included more than once, the data were aggregated as
described above. In addition, the donation time span cov-
ered by donations was color-coded by the number of days
for better visualization (Figure 6a–d). This analysis rev-
ealed no obvious distortion in participation days.
In addition, platelet donors with concomitant granu-
locyte or MNC donations had shorter self-reported URTI
durations (median of 3 and 4 days, n = 210 and 82,
respectively) than those who donated platelets alone
(median of 5 days, n = 1261). The difference was statisti-
cally significant for granulocyte donations (p = 0.008),
but not for MNC donations (p = 0.5).
Other factors potentially associated with URTI (public
transportation, professional contact to groups of children,
frequent social contacts, smoking, vitamin supplements,
fruit diet, physical exercise, sleep duration, and reported
stress) showed no conspicuous effects.
Interestingly, allergies improved more often in fre-
quent donors with a median annual platelet donation fre-
quency of 6.75 compared with those with a median of
2.75 donations per year (p = 0.07, rho = 0.10). However,
this difference was only detected in a small number of
cases (n = 15 of 314).
4 | DISCUSSION
This study shows that platelet donation with the Trima
Accel system, which uses an LRS chamber, leads to line-
arly dose-dependent lymphopenia. This effect varies
depending on the type of donation collection system. It
was strong and clearly visible in Trima Accel (LRS)
donors but weaker in donors whose donations were col-
lected using the Amicus system, which operates without
an LRS chamber. The total platelet donation count was
identified as the most important factor for
plateletpheresis-associated lymphopenia.
Plateletpheresis-associated lymphopenia was a special
focus of discussion in the 1980s. As platelet concentrates
obtained using older devices such as the Haemonetics
30 contained significant amounts of lymphocytes, donors
FIGURE 1 Neutrophil (turquoise), lymphocyte (yellow), and
monocyte (taupe) counts from 10,762 peripheral blood samples of
Trima/LRS platelet donors (dots) and predicted dependencies as a
function of annual platelet donation frequency (A) and total
platelet donation count (B) with logistic regression by generalized
additive models (lines) [Color figure can be viewed at
wileyonlinelibrary.com]
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previously lost up to 5  109 lymphocytes per dona-
tion.15–17 This type of lymphocyte loss was soon found to
be dependent on the type of apheresis system. It was
reduced from around 2.8  109 to 0.6  109 lymphocytes
by switching from the Haemonetics 30 device to the
Fenwal CS-3000, the precursor of the Amicus system.18
The introduction of leukoreduction has substantially
reduced donor lymphocyte loss even further. This raises
the question of the clinical relevance of plateletpheresis-
associated lymphopenia, as no adverse effects were
observed, even after several months of lymphopenia.9,
15, 18–22
Studies of lymphapheresis therapies for rheumatoid
arthritis or thoracic duct drainage involving the removal
of up to 130  109 lymphocytes during the course of
treatment revealed no specific susceptibility to bacterial
or fungal infections.20
Lymphopenia is generally associated with an
increased risk of infection,7, 23 increased mortality,24–26
and longer hospital stays.26 This was not recognized in
blood donors for many years. These concerns faded as
apheresis technologies improved. Eventually, new auto-
mated blood separation devices evolved that enabled the
production of leukocyte-depleted platelet concentrates
with a leukocyte content of less than 106, thus signifi-
cantly reducing lymphocyte losses.1
However, a recent analysis of very detailed and com-
plete data from the Swedish portion of the Scandinavian
Donations and Transfusions SCANDAT3-S database, pro-
viding data on blood donors, donations, components,
transfusions, and recipients from the mid-1990s to 2018,
revealed an increased risk of common bacterial infections
in apheresis donors with more than 50 donations col-
lected with an LRS chamber.8 As only data on inpatient
treatment of post-donation infectious complications are
TABLE 2 Changes in
hematological variables between the
initial and final blood counts
Variable Initial count Final count Change p
Recent donors (LRS donations)
WBCs (103/μL) 6.32 6.05 0.27 1.74  108
Lymphocytes (103/μL) 2.01 1.86 0.15 <2.2  1016
Monocytes (103/μL) 0.54 0.53 0.01 0.004682
Neutrophils (103/μL) 3.46 3.34 0.12 0.01144
Platelets (103/μL) 255 262 +7 1.29  1011
Hb (g/dL) 14.4 14.3 0.1 3.53  109
Historical donors (mostly non-LRS donations)
WBCs (103/μL) 6.20 6.06 0.14 0.001098
Lymphocytes (103/μL) 1.95 1.83 0.12 0.187
Monocytes (103/μL) 0.51 0.52 +0.01 0.8388
Neutrophils (103/μL) 3.44 3.18 0.26 0.2708
Platelets (103/μL) 249 243 6 1.58  1010
Hb (g/dL) 14.3 14.2 0.1 1.30  1014
Note: Results are shown as median of hematological values determined before the first and last donation in
the study period. Decreases are represented as negative change, and increases as positive change. p values
were determined by the Wilcoxon signed-rank test. All changes in the recent donors, whose plateletpheresis
donations were collected with a leukoreduction system chamber (LRS donations), were significant.
Significant declines in WBCs, platelets, and hemoglobin were detected in both groups.
FIGURE 2 Lymphocyte count as a function of annual platelet
donation frequency and cumulative platelet donation count in the
group of recent donors with LRS apheresis [Color figure can be
viewed at wileyonlinelibrary.com]
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included in the SCANDAT3-S database, the incidence
rates reported in the Swedish study (4.6 events per 1000
person-years among the most frequent donors and 4.1
per 1000 person-years for all donors with >90% LRS
donations) are much lower than those in the present
study (1372 events per 1000 person-years among LRS
donors in our recent data group), which was based on an
analysis of donor diary entries. In both cases, the dona-
tions were collected before Coronavirus social distancing
and face masking requirements. Therefore, although
74,408 donors were included in the Swedish study, the
observed association between LRS donations and the risk
of infection should be interpreted with caution consider-
ing the very small number of events (11 affected LRS
donors), the lack of multifactorial analysis to exclude
plasma donation bias there in contrast to the present
study (plasma donations were 14.7 times more frequent
than platelet donations in the Swedish data set), and dif-
ferences in the population characteristics. Moreover, the
proportion of females was 20.1% in the affected LRS
donor group compared with 50.5% in the comparison
group of the Swedish study.8
Concomitant donations of different blood products, as
in the Scandinavian study, are common.8 Some of our
donors were likewise granulocyte or mononuclear cell
donors. By concept, this would render the donor to a
much greater risk of lymphopenia. However, multifacto-
rial analysis failed to prove this effect. Instead, platelet
apheresis proved to be the most important factor for
lymphopenia.
Our study suggests that the type of cell separator used
has an impact on donor lymphocyte loss. While Gansner
et al.11 observed donation frequency-dependent CD4+
and CD8+ T-cell lymphopenia in frequent plat-
eletpheresis donors processed with the LRS-based Trima
Accel system, no severe CD4+ T-cell lymphopenia in fre-
quent plateletpheresis donors whose cells were collected
with the non-LRS Fenwal Amicus system in another
trial.27 Rhamani et al.,28 who examined the relationship
between lymphocyte counts and plateletpheresis with the
LRS-based Trima Accel, also found CD4+ T-cell
lymphopenia in previous frequent apheresis platelet
donors who had not donated for at least 1 year. This con-
tradicts the results of Richa et al.,10 who found no
lymphopenia in 471 donors collected with Trima Accel.
However, since the median number of platelet donations
was only four (range 1–34) and the median number of
platelet products donated was seven (range 2–65) over a
median of 72 weeks (range 0.3–131.3), and different indi-
vidual donation frequencies were not differentiated in
that study, the validity of its results could be considered
limited with regard to long-term frequent donors. The
median decrease in lymphocyte count between the first
and last donation was 3.7% in this aforementioned study.
FIGURE 3 Peripheral predonation blood lymphocyte count as a
function of (A) donor age and the number of (B) mononuclear cell
(MNC) and (C) granulocyte donations per year in the recent donor group
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This is similar to the median decrease in lymphocyte
count (7.5%) measured in the present study, but is well
below the decrease of 40% found in our frequent donors
with ≥26 apheresis platelet donations per year. This evi-
dence supports the theory that each plateletpheresis
donation contributes to a cumulative loss of lymphocytes,
which can result in a certain degree of lymphopenia over
the long-term in frequent plateletpheresis donors.
The observed lymphocyte loss in plateletpheresis
donors may be influenced by the type of WBC reduction
technology used during apheresis. While the Amicus sys-
tem achieves leukocyte reduction based on centrifugation
with the elution principle,29 Trima Accel uses an LRS
chamber with the countercurrent principle. Uncollected
WBCs are reinfused back to the donor by the Amicus sys-
tem, but remain in the LRS chamber of the Trima Accel.
Investigators have calculated different estimates for
the lymphocyte content of LRS chambers, which range
from about 0.6 to 1.4  109 WBC.3, 4, 11, 30, 31 This wide
variation can be explained by differences in anticoagulant
ratios, device settings, draw and return management,
processed blood volumes, and annual donation frequen-
cies between studies.11, 30 One study reports that the LRS
chamber caught 15%–20% of mononuclear cells passing
through the apheresis device.32 Accordingly, a rate of
26 donations per year would result in is a loss of at least
16  109 lymphocytes due to the content of lymphocytes
trapped in the LRS chambers.
This is a moderate number, as only 2.2% of all human
lymphocytes (approximately 10  109 lymphocytes) cir-
culate in the blood.33 While reduction of this pool
through apheresis appears evident, and exhaustion of the
replenishments would be assumed, other explanations
are possible. The circulating lymphocyte pool is not gen-
erated by overflow of marrow and lymphoid tissues,
where these cells come from, but rather substance of reg-
ulated release. Lower levels of circulating lymphocytes
after apheresis might therefore also been explained by
lowered lymphocyte target values within physiological
limits. This would explain why clinical signs of
lymphopenia are generally not known as blood donation
side effects.
However, lymphopenia does occur after blood dona-
tion and is evident by statistical methods. On an individ-
ual level, lymphocyte levels ranging from 1.0 to
1.5  103/μL of blood are classified as lymphopenia.7
Lymphopenia with less than 1.1  103 lymphocytes/μL
was observed in 4.0% of frequent donors in our LRS
group, whose median annual platelet donation frequency
was 12.7 compared with 6.1 in the overall LRS group.
Age might have contributed to lymphopenia in frequent
LRS donors, as their median age was 38.0 years compared
with 25.9 years in the overall LRS group. As donation
intensity was not evenly distributed through donor ages,
this retrospective analysis does not allow to draw conclu-
sions on age effects.
No negative impact of plateletpheresis-associated
lymphopenia on donor health was demonstrated in this
study. We found that low lymphocyte counts and a high
annual platelet donation frequency did not negatively
affect the frequency and duration of upper respiratory
tract diseases in recent plateletpheresis donors. Donors
FIGURE 4 (A) Neutrophil (taupe), lymphocyte (turquoise), and monocyte (yellow) counts from 1257 peripheral blood samples from
historical donors (dots), whose donations were collected mainly without a leukoreduction system chamber, and predicted dependencies from
the donation frequency as generalized additive model (lines), (B) lymphocyte count as a function of annual and cumulative platelet donation
rates in the historical group of donors with non-LRS apheresis [Color figure can be viewed at wileyonlinelibrary.com]
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on non-LRS plateletpheresis systems from the historic
group were not included in the questionnaire, as these
were less affected by lymphopenia, and there was no sus-
picion of infectious disease complications. In addition,
4.7% of our recent study participants reported an
improvement of allergies in connection with plat-
eletpheresis. However, this observation should be inter-
preted with caution, as only a few donors reported on
allergies, and this study did not have enough cases for
sufficient statistical power. Thus, pathophysiological
hypotheses based on mechanical stress to the cells and/or
changes in electrolytes are speculative. In particular, heat
shock protein expression by B cells was shown to be
upregulated by the mechanical stress of apheresis.34
The blood exposure to biomaterials during extracor-
poreal circulation has a modulating effect on the body's
own cells. Some investigators concluded that plat-
eletpheresis does not lead to an increase in platelet acti-
vation in donors,35, 36 while others found that the
exposure of blood to any foreign materials during plat-
eletpheresis could potentially result in the activation of
blood platelets, coagulation pathways (even if anticoagu-
lants are used), complement system activation and, thus,
to leukocyte activation.37, 38
According to Huang et al.,39 the adsorption of plasma
proteins to membrane surfaces in the extracorporeal cir-
cuit is one of the byproducts of this generalized activation
process. Ghio et al.40, 41 reported that plasma protein
adsorption during apheresis leads to the formation of
a boundary layer of soluble human leukocyte antigen
class 1 (sHLA-I) molecules, to which activated neutro-
phils and CD8+ T lymphocytes could bind and induce
multilevel immune modulation–a condition associated
with apoptosis and impairment of the immune system.41, 42
However, in contrast to therapeutic apheresis and dialy-
sis patients, healthy donors exhibited these as short-
lived effects, with no increase in the concentration
of transforming growth factor-beta-1 (TGFß1) in the
plasma.40, 41, 43 Therefore, Ghio et al.41, 44 did not find
any evidence suggesting that apheresis donors develop
any immunosuppressive side effects like bacterial, viral,
or neoplastic diseases. The tendency of allergies to
decrease after frequent plateletpheresis donations was
not mentioned in the literature.
Two positive aspects of the present study are the large
sample size of the donor population and the long follow-
up period for monitoring the hematological outcome var-
iables. Thirdly, we compared two different groups of
donors whose plateletpheresis donations were collected
with and without an LRS chamber at the same blood
donation center in different time periods. Moreover, the
continuous prospective capture of clinical immune status
assessment data before each donation by questionnaire is
FIGURE 5 Impact of annual platelet donation frequency, total
platelet donation count, concomitant granulocyte donation, and
concomitant MNC donation on lymphocyte count. Shown are the results
of (A) exploratory maximum-likelihood factor analysis, (B) random forest
analysis of the importance of these variables for lymphocyte count, and
(C) recursive regression tree analysis. In the latter case, the average group
lymphocyte count is shown as 106/mL inside ovals; the left branches
indicate cases where the condition is met, and the right branches show
where it is not [Color figure can be viewed at wileyonlinelibrary.com]
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a feature that distinguishes the present study from others,
in spite of the fact that the questionnaire survey period
was relatively short and based on donor self-assessments.
However, the donors alone were responsible for
maintaining their personal diary of colds and allergies, and
there was no non-donor control group. One of the main
limitations of the retrospective study design was poor com-
parability of the historical donors with non-LRS apheresis
and recent donors with LRS apheresis because differential
blood counts could only be obtained retrospectively. Other
limitations include the lack of randomization of donors to
LRS and non-LRS apheresis, the lack of lymphopenia sever-
ity classification in the various lymphocyte subgroups, and
the lack of testing for functional changes in the cells.
5 | CONCLUSION
In summary, this study demonstrated a significant associ-
ation between frequent plateletpheresis using apheresis
devices with an LRS chamber and reduced lymphocyte
counts, but the duration of this lymphopenia remains
unclear. Our findings do not suggest that plateletpheresis-
associated lymphopenia harms the donors' immune com-
petence, but the theory that apheresis may induce changes
in the immune system remains plausible. Blood donation
services may therefore want to ensure complete flushings
of the entire apheresis tubing system with LRS chambers.
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